Product Code: GMDHC2390TDB
Summary:
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor Beta - Pipeline Review, H1 2020, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.
The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 5 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Musculoskeletal Disorders, Women's Health, Genetic Disorders, Hormonal Disorders, Immunology, Male Health and Metabolic Disorders which include indications Multiple Sclerosis, Osteoporosis, Alzheimer's Disease, Breast Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Colon Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hormone Sensitive Breast Cancer, Inflammation, Leiomyosarcoma, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic's Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer, Post Menopausal Mood Disorder, Precocious Puberty, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
Furthermore, this report also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
- The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics
Reasons to Buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
List of Tables
List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Atossa Therapeutics Inc
- Avivia BV
- Eagle Pharmaceuticals Inc
- Eli Lilly and Co
- Endece LLC
- EndoCeutics Inc
- Helixmith Co Ltd
- Huons Co Ltd
- Karo Pharma AB
- Kissei Pharmaceutical Co Ltd
- MEI Pharma Inc
- Oasmia Pharmaceutical AB
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles
- (bazedoxifene acetate + cholecalciferol) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- acolbifene + prasterone - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AUS-131 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dehydrodiconiferyl alcohol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- erteberel - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- estradiol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fosfestrol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fulvestrant - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fulvestrant - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fulvestrant - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KB-3944 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KB-9520 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Libidua - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Loseasonique - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NDC-1308 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Agonize ESR2 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize ESR2 for Multiple Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SR-16234 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products
- Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones
- Featured News & Press Releases
- Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
- Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology
- Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
- Mar 27, 2019: Combo better for HR+ breast cancer patients
- Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
- Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
- Oct 04, 2018: Mayo researchers identify potential new treatment for subset of women with triple-negative breast cancer
- Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
- Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
- Dec 11, 2017: AstraZeneca's Faslodex Rejects For Use Within NHS Scotland
- Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
- Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
- Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
- Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
- Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
